

2021 Faculty Disclosure

Thursday 6/10/21

Griffin Cupstid, MD, Spartanburg SC.

DISCLOSURE: Neither Dr. Cupstid, nor any member of his immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. Review knowledge base for relevant topics
2. Complete the ABFM self-assessment test
3. Claim certification credits for board certification

Friday 6/11/21

Nick Ulmer, MD, Laurens, SC

DISCLOSURE: Neither Dr. Ulmer, nor any member of his immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. Know the definitions of the types of conditions that we use in our evaluation and management services as well as how to determine whether a patient is new or established in a practice.
2. Understand how to correctly apply time based coding in the ambulatory office practice setting.
3. Define 2021 Medical Decision Making components and be able to correctly apply them.

Alice Harris, JD, Columbia SC

DISCLOSURE: Neither Ms. Harris, nor any member of her immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. Know who is Auditing Claims and Current Audit topics
2. Know how to effectively manage and defend payor audits
3. Prevent payor audits and reduce risk through effective proactive compliance.

Douglas Furmanek. PharmD.

DISCLOSURE: Neither Dr. Furmanek, nor any member of his immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. Understand the current opioid epidemic impact on the US and South Carolina.
2. Identify pain management strategies that health care providers can use in the current opioid epidemic.
3. Understand national and state legislation to mitigate the opioid epidemic.

Ada Stewart, MD, AAFP President

DISCLOSURE: Neither Dr. Stewart, nor any member of her immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. President- American Academy of Family Physicians - Update from your National Academy
2. Describe Advocacy Efforts.
3. Strategic Priorities

Saturday 6/12/21

Divya Ahuja, MD

DISCLOSURE: Neither Dr. Ahuja, nor any member of his immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. Discuss the current state of the pandemic.
2. Understand treatment for moderate and severe Covid-19
3. Understand prevention measures including vaccines and variants

Douglas Furmanek, PharmD.

DISCLOSURE: Neither Dr. Furmanek, nor any member of his immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. Understand the current opioid epidemic impact on the US and South Carolina.
2. Identify pain management strategies that health care providers can use in the current opioid epidemic.
3. Understand national and state legislation to mitigate the opioid epidemic.

Darra James Coleman

DISCLOSURE: Neither Ms. Coleman, nor any member of her immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. Attendees will be able to identify their obligations prior to prescribing Schedule II controlled substances in South Carolina.
2. Attendees will be able to identify the prerequisites and limitations for prescribing controlled substances via telemedicine in South Carolina.
3. Attendees will understand the prima facie conflicts regarding delegation in physician dispensing.

Elizabeth Baxley, MD

DISCLOSURE: Neither Dr. Baxley, nor any member of her immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. Identify the core requirements for continuous certification through ABFM.
2. Describe recent changes to PI activity options, the new FMCLA alternative and KSA revisions
3. Know of ABFMs interest in engaging diplomates

Sunday 6/12/21

Stewart Tepper, MD

DISCLOSURE: Dr. Tepper has indicated the following financial relationships and or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Research grants from Allergan, Inc., Amgen, Inc., electroCore Inc., Eli Lilly and Company, Lundbeck Pharmaceuticals, Inc., Neuroliel Ltd., Novartis Pharmaceuticals Corporation, Satsuma Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and osano Pharma Corporation. He is also a consultant and/or a member of the Advisory Boards of Aeon Biopharma Inc., Allergan, Inc., Amgen, Inc., Aperture Venture Partners, LLC, Aralez Pharmaceuticals Canada Inc., Axsome Therapeutics, Inc., Becker Pharmaceutical Inc., ClearView Healthcare Partners, CRG, Currax Pharmaceuticals LLC, Eli Lilly and Company, GLG, Guidepoint Global, Healthcare Consultancy Group, Health Science Communications, Impel NeuroPharma, Lundbeck Pharmaceuticals, Inc., Medicxi, Neuroliel Ltd., Novartis Pharmaceuticals Corporation, PULMATRiX, Inc., Reckner Healthcare, Relevale Inc., SAI MedPartners, Satsuma Pharmaceuticals, Inc., Spherix Global Insights, Synapse Medical Communications, Theranica Bio-Electronics Ltd., Xoc Pharmaceuticals, Inc., Zosano Pharma Corporation.

Objectives:

1. Appreciate the prevalence of migraine in a primary care setting
2. Utilize established criteria to make differential diagnoses for migraine headache and to distinguish episodic from chronic migraine
3. Assess the evidence regarding the potential benefits and risks of emerging acute migraine treatments

Wayne Weart, PharmD

DISCLOSURE: Neither Dr. Weart, nor any member of his immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. At the completion of this activity, the provider will be able to:
2. Discuss the new guidelines for patients with asthma, COPD, dyslipidemia and Type 2 diabetes and the evidence on which they are based, and how to apply them in selected patients
3. Describe the current information concerning selected newly FDA approved medications (pharmacology, pharmacokinetics, efficacy and safety data, drug interactions, dosing, monitoring, and cost) in the selection of evidence-based pharmacotherapy.

Gerald Wilson, MD

DISCLOSURE: Dr. Wilson has indicated the following financial relationships and or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices. Dr. Wilson has disclosed that he is a Board member at Absolute Total Care.

Objectives:

1. Understanding the significantly higher cancer incidence and mortality rates among African American men in SC
2. Understanding the leading disparities facing African American men in SC
3. Understanding the evidence based interventions to increase cancer related screening among screen able cancers in SC

Stephanie Hinton, CMP

DISCLOSURE: Neither Stephanie Hinton, nor any member of her immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services. The content of his material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices.

Objectives:

1. Understanding the significantly higher cancer incidence and mortality rates among African American men in SC
2. Understanding the leading disparities facing African American men in SC
3. Understanding the evidence based interventions to increase cancer related screening among screen able cancers in SC